• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验

Treatment Effectiveness of Venetoclax-Based Therapy After Bruton Tyrosine Kinase Inhibitors in Chronic Lymphocytic Leukemia: An International Real-World Study.

作者信息

Ghosh Nilanjan, Eyre Toby A, Brown Jennifer R, Lamanna Nicole, Manzoor Beenish S, Coombs Catherine C, Tuncer Hande H, Ujjani Chaitra, Leslie Lori A, Roeker Lindsey E, Davids Matthew S, Rhodes Joanna M, Skarbnik Alan P, Sinai Wendy, Fleury Isabelle, Hill Brian T, Martinez-Calle Nicolas, Barr Paul M, Jawaid Dureshahwar, Emechebe Nnadozie, Pearson Laurie, Lansigan Frederick, Choi Yun, Jensen Christopher E, Fakhri Bita, Stephens Deborah M, Marx Steven E, Schuster Stephen J, Coyle Michael, Pivneva Irina, Watson Talissa, Guerin Annie, Shadman Mazyar

机构信息

Levine Cancer Institute, Atrium Health, Wake Forest University School of Medicine, Charlotte, North Carolina, USA.

Churchill Hospital, Oxford University, Oxford, UK.

出版信息

Am J Hematol. 2025 Mar;100(3):511-515. doi: 10.1002/ajh.27563. Epub 2024 Dec 19.

DOI:10.1002/ajh.27563
PMID:39698781
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC11803543/
Abstract
摘要

相似文献

1
Treatment Effectiveness of Venetoclax-Based Therapy After Bruton Tyrosine Kinase Inhibitors in Chronic Lymphocytic Leukemia: An International Real-World Study.布鲁顿酪氨酸激酶抑制剂治疗后，维奈托克为基础的疗法在慢性淋巴细胞白血病中的治疗效果：一项国际真实世界研究
Am J Hematol. 2025 Mar;100(3):511-515. doi: 10.1002/ajh.27563. Epub 2024 Dec 19.
2
Real-World Health Care Resource Use and Costs Among Patients With Chronic Lymphocytic Leukemia Treated With Venetoclax-Based and Bruton Tyrosine Kinase Inhibitor-Based Regimens in the Second-Line Setting.在二线治疗环境中，接受 Venetoclax 为基础和 Bruton 酪氨酸激酶抑制剂为基础方案治疗的慢性淋巴细胞白血病患者的真实世界卫生保健资源利用和成本。
JCO Oncol Pract. 2024 Aug;20(8):1132-1139. doi: 10.1200/OP.23.00630. Epub 2024 Apr 16.
3
Real-world comparative effectiveness of venetoclax-obinutuzumab versus Bruton tyrosine kinase inhibitors for frontline chronic lymphocytic leukaemia.真实世界中维奈托克-奥滨尤妥珠单抗对比布鲁顿酪氨酸激酶抑制剂用于慢性淋巴细胞白血病一线治疗的疗效比较。
Br J Haematol. 2024 Oct;205(4):1395-1403. doi: 10.1111/bjh.19613. Epub 2024 Jul 24.
4
Comparison Between Venetoclax-based and Bruton Tyrosine Kinase Inhibitor-based Therapy as Upfront Treatment of Chronic Lymphocytic Leukemia (CLL): A Systematic Review and Network Meta-analysis. Venetoclax 与 Bruton 酪氨酸激酶抑制剂在慢性淋巴细胞白血病（CLL）一线治疗中的比较：系统评价和网络荟萃分析。
Clin Lymphoma Myeloma Leuk. 2021 Apr;21(4):216-223. doi: 10.1016/j.clml.2020.10.012. Epub 2020 Oct 29.
5
Venetoclax Consolidation After Bruton Tyrosine Kinase Inhibitor Treatment for Patients With Chronic Lymphocytic Leukemia.布鲁顿酪氨酸激酶抑制剂治疗慢性淋巴细胞白血病患者后的维奈托克巩固治疗
EJHaem. 2025 Jun 25;6(4):e70085. doi: 10.1002/jha2.70085. eCollection 2025 Aug.
6
BTK Inhibitors Versus Venetoclax as First- or Second-Line Therapy in Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma: A Real-World Evidence Study.布鲁顿酪氨酸激酶抑制剂与维奈克拉作为慢性淋巴细胞白血病/小淋巴细胞淋巴瘤一线或二线治疗的比较：一项真实世界证据研究
Am J Hematol. 2025 Apr;100(4):720-723. doi: 10.1002/ajh.27639. Epub 2025 Feb 17.
7
Efficacy and safety of new-generation Bruton tyrosine kinase inhibitors in chronic lymphocytic leukemia/small lymphocytic lymphoma: a systematic review and meta-analysis.新一代布鲁顿酪氨酸激酶抑制剂在慢性淋巴细胞白血病/小淋巴细胞淋巴瘤中的疗效和安全性：系统评价和荟萃分析。
Ann Hematol. 2024 Jul;103(7):2231-2244. doi: 10.1007/s00277-023-05486-x. Epub 2023 Oct 16.
8
Real-World Effectiveness of Frontline Treatments Among Patients with Chronic Lymphocytic Leukemia: Results from ConcertAI.慢性淋巴细胞白血病患者一线治疗的真实世界疗效：来自ConcertAI的结果
Cancers (Basel). 2025 Feb 26;17(5):799. doi: 10.3390/cancers17050799.
9
Pirtobrutinib venetoclax in covalent Bruton tyrosine kinase inhibitor-pretreated chronic lymphocytic leukemia: a matching-adjusted indirect comparison.共价 Bruton 酪氨酸激酶抑制剂预处理的慢性淋巴细胞白血病中泊马度胺联合维奈克拉：匹配调整的间接比较。
Haematologica. 2024 Jun 1;109(6):1866-1873. doi: 10.3324/haematol.2023.284150.
10
Three-year cardiovascular and non-cardiovascular adverse events in patients with chronic lymphocytic leukemia or small cell lymphocytic lymphoma treated with Bruton tyrosine kinase inhibitors acalabrutinib or ibrutinib: a real-world analysis.采用布鲁顿酪氨酸激酶抑制剂阿卡替尼或伊布替尼治疗的慢性淋巴细胞白血病或小细胞淋巴瘤患者的 3 年心血管和非心血管不良事件：真实世界分析。
Ann Hematol. 2024 Nov;103(11):4613-4620. doi: 10.1007/s00277-024-05921-7. Epub 2024 Aug 17.

引用本文的文献

1
Bruton's Tyrosine Kinase (BTK) Mutations in Chronic Lymphocytic Leukemia (CLL): A Clinical View.慢性淋巴细胞白血病（CLL）中的布鲁顿酪氨酸激酶（BTK）突变：临床视角
Mediterr J Hematol Infect Dis. 2025 Jul 1;17(1):e2025053. doi: 10.4084/MJHID.2025.053. eCollection 2025.
2
Phase III Trial of Pirtobrutinib Versus Idelalisib/Rituximab or Bendamustine/Rituximab in Covalent Bruton Tyrosine Kinase Inhibitor-Pretreated Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (BRUIN CLL-321).在接受共价布鲁顿酪氨酸激酶抑制剂预处理的慢性淋巴细胞白血病/小淋巴细胞淋巴瘤患者中进行的pirtobrutinib与idelalisib/利妥昔单抗或苯达莫司汀/利妥昔单抗对比的III期试验（BRUIN CLL-321）
J Clin Oncol. 2025 Aug;43(22):2538-2549. doi: 10.1200/JCO-25-00166. Epub 2025 Jun 6.
3
Real-World Effectiveness of Frontline Treatments Among Patients with Chronic Lymphocytic Leukemia: Results from ConcertAI.慢性淋巴细胞白血病患者一线治疗的真实世界疗效：来自ConcertAI的结果
Cancers (Basel). 2025 Feb 26;17(5):799. doi: 10.3390/cancers17050799.
4
Resistance mechanisms and approach to chronic lymphocytic leukemia after BTK inhibitor therapy.BTK抑制剂治疗后慢性淋巴细胞白血病的耐药机制及应对方法
Leuk Lymphoma. 2025 Jul;66(7):1176-1188. doi: 10.1080/10428194.2025.2466101. Epub 2025 Feb 19.
5
A Review of Resistance Mechanisms to Bruton's Kinase Inhibitors in Chronic Lymphocytic Leukemia.慢性淋巴细胞白血病中布鲁顿酪氨酸激酶抑制剂耐药机制的研究进展。
Int J Mol Sci. 2024 May 11;25(10):5246. doi: 10.3390/ijms25105246.

本文引用的文献

1
Venetoclax-rituximab is active in patients with BTKi-exposed CLL, but durable treatment-free remissions are uncommon.维奈克拉联合利妥昔单抗对曾接受布鲁顿酪氨酸激酶抑制剂（BTKi）治疗的慢性淋巴细胞白血病（CLL）患者有活性，但持久的无治疗缓解并不常见。
Blood Adv. 2024 Mar 26;8(6):1439-1443. doi: 10.1182/bloodadvances.2023011327.
2
Clinical efficacy and tolerability of venetoclax plus rituximab in patients with relapsed or refractory chronic lymphocytic leukemia-a real-world analysis of the Polish Adult Leukemia Study Group. Venetoclax 联合利妥昔单抗治疗复发或难治性慢性淋巴细胞白血病患者的临床疗效和耐受性：波兰成人白血病研究组的真实世界分析。
Ann Hematol. 2023 Aug;102(8):2119-2126. doi: 10.1007/s00277-023-05304-4. Epub 2023 Jul 1.
3
Treatment of Chronic Lymphocytic Leukemia After Discontinuation of Bruton's Tyrosine Kinase Inhibitors.布鲁顿酪氨酸激酶抑制剂停药后慢性淋巴细胞白血病的治疗。
Hematol Oncol Clin North Am. 2021 Aug;35(4):793-806. doi: 10.1016/j.hoc.2021.03.008. Epub 2021 May 27.
4
Current and future treatment strategies in chronic lymphocytic leukemia.慢性淋巴细胞白血病的当前和未来治疗策略。
J Hematol Oncol. 2021 Apr 26;14(1):69. doi: 10.1186/s13045-021-01054-w.
5
Efficacy of venetoclax monotherapy in patients with relapsed chronic lymphocytic leukaemia in the post-BCR inhibitor setting: a UK wide analysis.在 BCR 抑制剂治疗后复发的慢性淋巴细胞白血病患者中，venetoclax 单药治疗的疗效：英国范围内的分析。
Br J Haematol. 2019 May;185(4):656-669. doi: 10.1111/bjh.15802. Epub 2019 Feb 15.
6
Venetoclax for chronic lymphocytic leukaemia progressing after ibrutinib: an interim analysis of a multicentre, open-label, phase 2 trial.依鲁替尼治疗后进展的慢性淋巴细胞白血病的维奈托克：多中心、开放标签、2 期试验的中期分析。
Lancet Oncol. 2018 Jan;19(1):65-75. doi: 10.1016/S1470-2045(17)30909-9. Epub 2017 Dec 12.